Actively Recruiting
A Retrospective Clinical Study on the First-line Maintenance Treatment of Peripheral T-cell Lymphoma (PTCL) With Chidamide
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2023-08-01
200
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the safety and effectiveness of chidamide when used as a first-line maintenance therapy for patients diagnosed with peripheral T-cell lymphoma (PTCL). The study involves a retrospective analysis, collecting past patient data to better understand how chidamide works in this specific treatment setting. Researchers collected detailed information from patients diagnosed with PTCL who received chidamide as maintenance therapy after their initial treatment. The data includes demographics, prior treatments, and results from various tests such as blood work, bone marrow studies, pathology, flow cytometry, next-generation sequencing, and PET-CT scans. The study focuses on assessing chidamide's role during this maintenance phase. Participants' medical records are reviewed for several outcomes, including progression-free survival over two years, overall survival, complete response rates, and duration of response. Safety data is also analyzed based on these records. This retrospective study does not require active treatment or visits but involves thorough examination of existing clinical data collected at the study center.
CONDITIONS
Brief Title
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years and older
- Male or female gender
- Diagnosed with peripheral T-cell lymphoma (PTCL)
- Received chidamide as maintenance therapy after first-line treatment
You will not qualify if you...
- Patients diagnosed with lymphomas other than PTCL
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years
Participants who have received chidamide as first-line maintenance therapy for PTCL are observed retrospectively through collected clinical data and imaging results.
Data collected from past clinical visits and imaging
Trial Site Locations
Total: 1 location
1
Hematological Department, People's Hospital of Jiangsu Province
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
W
wei xu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here